检索结果-南通市图书馆

Chinese Medical Journal 2024年第4期137卷 487-489页

作者： Cong Li Fengzhu Guo jingtong zhai Xiaohan Liu Zhijun Li Binghe Xu Department of Medical Oncology National Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China Department of Medical Oncology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing 100730China Department of Histology and Embryology Basic Medical CollegeChina Medical UniversityShenyangLiaoning 110122China

To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer *** data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.

关键词： breast immunotherapy chemotherapy

Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2022年第4期34卷 343-352页

作者： Dan Lyu Binliang Liu Bo Lan Xiaoying Sun Lixi Li jingtong zhai Haili Qian Fei Ma Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Breast Cancer Medical Oncology Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of MedicineCentral South UniversityChangsha 410013China Department of Medical Oncology Cancer Hospital of Huanxing Chaoyang DistrictBeijing 100122China State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Objective: The mechanism of acquired gene mutation plays a major role in resistance to endocrine therapy in hormone receptor(HR)-positive advanced breast cancer. Circulating tumor DNA(ctDNA) has been allowed for the assessment of the genomic profiles of patients with advanced cancer. We performed this study to search for molecular markers of endocrine therapy efficacy and to explore the clinical value of ctDNA to guide precise endocrine therapy for HR-positive/human epidermal growth factor receptor-2(HER-2)-negative metastatic breast cancer ***: In this open-label, multicohort, prospective study, patients were assigned to four parallel cohorts and matched according to mutations identified in ctDNA: 1) activation of the phosphatidylinositol-3-kinase(PI3K)/AKT/mammalian target of rapamycin(mTOR) signaling pathway preferred mTOR inhibitor combined with endocrine therapy;2) estrogen receptor 1(ESR1) mutation preferred fulvestrant;3) HER-2 mutations preferred pyrotinib;and 4) no actionable mutations received treatment according to the clinical situation. In all cohorts, patients were divided into compliance group and violation group. The primary outcome measure was progression-free survival(PFS), and the secondary outcome measure was overall survival(OS).Results: In all cohorts, the combined median PFS was 4.9 months, and median PFS for the compliance and violation groups was 6.0 and 3.0 months, respectively [P=0.022, hazard ratio(HR)=0.57]. Multivariate Cox regression model showed the risk of disease progression was lower in compliance group than in violation group(P=0.023, HR=0.55). Among the patients with HER-2 mutations, the median PFS was 11.1 months in the compliance group and 2.2 months in the violation group(P=0.011, HR=0.20). There was no significant difference in the median PFS between patients who did and did not comply with the treatment protocol in patients with activation of the PI3K/AKT/mTOR or ESR1 ***: The results suggest th

关键词： ctDNA next-generation sequencing breast cancer endocrine therapy

Advances in medical treatment of breast cancer in 2022

在线全文

学校读者我要写书评

暂无评论

Cancer Innovation 2023年第1期2卷 1-17页

作者： jingtong zhai Yun Wu Fei Ma Virginia Kaklamani Binghe Xu Department of Medical Oncology National Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Division of Hematology OncologyUT Health San Antonio MD Anderson Cancer CenterSan AntonioTexasUSA

Breast cancer has replaced lung cancer as the most common malignancy *** 5‐year survival rate of breast cancer has reached 90%.Systemic treatment of breast cancer has developed into a mature system including chemotherapy,targeted therapy,endocrine therapy and *** article summarizes the annual progress of breast cancer chemotherapy,targeted therapy,endocrine therapy and immunotherapy in 2022,providing valuable information for future research to better guide individualized treatment of breast cancer,thereby improving the prognosis and quality of life of breast cancer patients.

关键词： breast cancer chemotherapy targeted therapy endocrine therapy immunotherapy

Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第7期8卷 3524-3535页

作者： Cong Li Shi Qiu Xiaohan Liu Fengzhu Guo jingtong zhai Zhijun Li Linghui Deng Liming Ge Haili Qian Lu Yang Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China State Key Laboratory of Molecular Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Urology Institute of Urology and National Clinical Research Center for GeriatricsWest China Hospital of Sichuan UniversityChengdu 610041China National Clinical Research Center of Geriatrics The Center of Gerontology and GeriatricsWest China HospitalSichuan UniversityChengdu 610065China Institute of Oncology Research(IOR) Oncology Institute of Southern Switzerland(IOSI)Bellinzona 6500Switzerland Department of Histology and Embryology Basic Medical CollegeChina Medical UniversityShenyangLiaoning 110122China Department of Pharmaceutical and Bioengineering School of Chemical EngineeringSichuan UniversityChengdu 610065China

The extracellular matrix(ECM)serves as signals that regulate specific cell states in tumor *** evidence suggests that extracellular biomechanical force signals are critical in tumor *** this study,we aimed to explore the influence of ECM-derived biomechanical force on breast cancer cell *** were conducted using 3D collagen,fibrinogen.

关键词： breast cancer matrix

Antibody-drug conjugates in HER2-positive breast cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2022年第3期135卷 261-267页

作者： Lixi Li Di Zhang Binliang Liu Dan Lv jingtong zhai Xiuwen Guan Zongbi Yi Fei Ma Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China

Antibody-drug conjugates(ADCs)combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic *** anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies,direct action and bystander effect of cytotoxic drugs,and antibody-dependent cell-mediated cytotoxicity and complement-dependent *** have been used in adjuvant therapy and rescue treatment of human epidermal receptor 2(HER2)-positive breast cancer,greatly improving the prognosis of breast cancer *** ongoing clinical trials of ADC for breast cancer and other solid tumors proved the potential of ADCs will provide more promising treatment options for patients with malignant *** review introduces the mechanism and latest clinical progress of ADC drugs approved for HER2-positive breast cancer to guide clinical practice and conduct research.

关键词： Antibody-drug conjugate HER2-positive Breast cancer T-DM1 DS-8201

High BRCA1 expression is an independent prognostic biomarker in LUAD and correlates with immune infiltration

在线全文

学校读者我要写书评

暂无评论

Cancer Innovation 2023年第2期2卷 91-95页

作者： Fengzhu Guo Cong Li Shuning Liu Zhijun Li jingtong zhai Zhiwu Wang Binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of Medical Oncology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijingChina Department of Chemoradiotherapy Tangshan People's HospitalTangshanChina

Non-small-cell lung cancer(NSCLC)is the primary histopathological subtype of lung cancer and accounts for around 82%of all pulmonary neoplasms[1].Breast cancer susceptibility gene 1(BRCA1)is a tumor suppressor gene that regulates cellular responses to stress through DNA damage repair and is frequently mutated in breast and ovarian cancers[2].Furthermore,previous studies have increasingly shown that the expression of BRCA1 and the relevant poly(ADP-ribose)polymerase inhibitors is related to the prognosis and therapeutic response of other tumors,including lung cancer[3,4].However,previous findings on the prognostic value of BRCA1 for NSCLC have been inconsistent or conflicting,which may be attributed to the small number of patients from a single center or disparity in the ratio of patients with lung adenocarcinoma(LUAD)versus squamous cell carcinoma(LUSC)[5].The aim of this study was to determine the prognostic value of BRCA1 in NSCLC and its association with immune infiltration.

关键词： bioinformatics analysis lung adenocarcinoma meta-analysis non-small-cell lung cancer prognosis

城市规模、创新能力与空间溢出效应——以长江三角洲城市群为例

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

当代经济管理 2020年第12期42卷 30-37页

作者：翟婧彤张军涛东北财经大学公共管理学院辽宁大连116025

以创新驱动经济增长,激发城市活力和竞争力,是实现经济高质量发展的关键。运用动态面板模型和空间面板模型,以2005—2017年长三角城市群地级及以上城市为研究对象,从人口、空间、经济三个维度探讨了城市规模对创新能力及其空间溢出效应... 详细信息

以创新驱动经济增长,激发城市活力和竞争力,是实现经济高质量发展的关键。运用动态面板模型和空间面板模型,以2005—2017年长三角城市群地级及以上城市为研究对象,从人口、空间、经济三个维度探讨了城市规模对创新能力及其空间溢出效应的影响和作用机理。结果表明:城市创新能力存在明显的空间溢出效应,且相关性随时间逐渐增强;城市创新能力的空间分布特征分化明显,呈现以上海为中心的高-高集聚和城市群北部低-低集聚;人口规模与创新能力存在“倒U型”关系,与创新能力的空间溢出效应具有显著负相关关系;人力资本结构与城市创新能力在人口规模的调节效应下显著正相关;经济规模和空间规模的增加能够显著提升城市创新能力,但对于空间溢出效应的影响并不显著。

关键词：城市规模创新能力空间溢出效应莫兰指数空间杜宾模型

我国城市居民通勤方式选择及影响因素研究——以天津市为例

在线全文

学校读者我要写书评

暂无评论

城市发展研究 2016年第7期23卷 108-115页

作者：王丽艳贾宾翟婧彤天津城建大学经济与管理学院天津大学京津冀协同发展研究中心

厘清城市居民通勤出行特征,揭示其内在规律,为解决城市交通问题提供重要依据。基于天津市居民通勤特征调查,综合考虑智能手机信息化效应,建立结构方程模型,分析城市居民通勤方式选择的典型特征及其影响因素。结果显示:城市居民的个人属... 详细信息

厘清城市居民通勤出行特征,揭示其内在规律,为解决城市交通问题提供重要依据。基于天津市居民通勤特征调查,综合考虑智能手机信息化效应,建立结构方程模型,分析城市居民通勤方式选择的典型特征及其影响因素。结果显示:城市居民的个人属性、家庭现状、住房类型、职住地附近公共交通环境等因素对居民通勤方式与通勤时间作用显著,现阶段地铁分担率较低,公共交通线路和站点覆盖不足;智能手机的信息化效应对公共交通模式较为显著,对居民通勤时间、路线选择具有显著影响。最后提出相应对策建议:优化城市公共交通系统、促进职住平衡、减轻低收入群体通勤负担、加快智能交通系统建设等。

关键词：通勤效率智能手机结构方程通勤方式

城市规模与人力资本技能溢价:集聚效应和选择效应

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

统计研究 2021年第2期38卷 73-86页

作者：张军涛翟婧彤贾宾东北财经大学公共管理学院南开大学经济学院

本文利用2013年中国家庭收入调查(CHIP)的个人样本数据与《中国城市统计年鉴》数据,考察城市规模与异质性劳动力收入和人力资本技能溢价的关系,并结合城市集聚经济理论和空间知识经济理论对其内在影响机制进行剖析与实证检验。结果显示... 详细信息

本文利用2013年中国家庭收入调查(CHIP)的个人样本数据与《中国城市统计年鉴》数据,考察城市规模与异质性劳动力收入和人力资本技能溢价的关系,并结合城市集聚经济理论和空间知识经济理论对其内在影响机制进行剖析与实证检验。结果显示:大城市在集聚效应和选择效应的作用下具有更高的劳动力名义工资和技能溢价水平;考虑不同规模城市的生活成本差异后,补偿效应会部分抵消大城市的工资溢价,对劳动者的实际收入产生消极影响,从而弱化大城市的技能溢价水平。进一步的非线性效应分析发现,城市规模与劳动力名义收入和实际收入分别存在倒U型和正U型关系;通过比较城市规模对不同收入群体技能溢价的差异性影响验证了群分效应的存在。研究结果对于新型城镇化过程中不同规模等级城市人才政策的制定以及技能异质性劳动力的就业选择具有重要的现实意义和参考价值。

关键词：城市规模劳动力收入技能溢价集聚效应选择效应

在线全文

学校读者我要写书评

暂无评论

公路工程沥青路面施工技术和质量控制措施

山西建筑 2018年第33期44卷 118-119页

作者：翟精通山西省公路局运城分局山西运城044000

苏锡常南部高速公路位于江苏省南部,是勾连江苏南部发达区域的重要交通要道与经济动脉,有着良好的经济效益、社会效益。以苏锡常南部高速公路沥青路面为例,从混合料配比、路面摊铺、路面碾压以及接缝施工四个角度分析了公路沥青路面施... 详细信息

苏锡常南部高速公路位于江苏省南部,是勾连江苏南部发达区域的重要交通要道与经济动脉,有着良好的经济效益、社会效益。以苏锡常南部高速公路沥青路面为例,从混合料配比、路面摊铺、路面碾压以及接缝施工四个角度分析了公路沥青路面施工技术,就如何加强公路工程沥青路面施工质量控制提出了几点建议。

关键词：公路工程沥青路面施工技术质量控制